Carr K W, Engler R L, Ross J
West J Med. 1982 Apr;136(4):295-308.
Coronary artery bypass operations improve survival in patients with symptomatic left main coronary artery stenosis, but whether or not longevity is improved in other patients has been controversial. Small clinical studies, even when randomized, have not sufficiently controlled for the heterogeneous distribution of risk factors in patient cohorts treated medically and surgically. The first randomized study large enough to overcome such problems, the Veterans Administration Cooperative Study, showed that coronary artery bypass procedures prolonged survival only in the high-risk subgroup. The surgically treated patients suffered more perioperative morbidity and mortality and had worse long-term survival than similar patients operated on in more recent years. The European Coronary Surgery Study Group recently reported that the three-year to five-year survival of symptomatic patients with triple-vessel disease and normal left ventricular function was better if patients were randomly assigned to surgical therapy. The third and by far the largest randomized study, the Coronary Artery Surgery Study (CASS), has not yet reported long-term follow-up results. Large clinical studies, both randomized and nonrandomized, that have subgrouped patients by the number of diseased coronary arteries and by the degree of left ventricular dysfunction all show that survival with single-vessel disease is excellent and not improved by operation. Medically treated patients with double- and triple-vessel disease who have good left ventricular function generally now have a five-year survival greater than 85 percent and only two of the major studies suggest that it is improved by operation. The results of most studies, however, suggest that bypass operation prolongs survival in symptomatic patients when left ventricular dysfunction coexists with double- and triple-vessel disease. Continually improving surgical techniques may potentiate the small survival differences that are now apparent, but until then, because the survival differences are so small, it is recommended that limiting anginal symptoms remain the primary indication for a coronary bypass procedure for an individual patient.
冠状动脉搭桥手术可提高有症状的左主干冠状动脉狭窄患者的生存率,但该手术能否延长其他患者的寿命一直存在争议。小型临床研究,即使是随机对照研究,也未能充分控制接受内科治疗和外科治疗的患者队列中危险因素的异质性分布。首个规模大到足以克服此类问题的随机研究——退伍军人管理局合作研究表明,冠状动脉搭桥手术仅能延长高危亚组患者的生存期。与近年来接受手术的类似患者相比,接受手术治疗的患者围手术期发病率和死亡率更高,长期生存率更差。欧洲冠状动脉外科研究小组最近报告称,对于有症状的三支血管病变且左心室功能正常的患者,如果将其随机分配至手术治疗组,其3年至5年生存率会更高。第三个也是迄今为止最大的随机研究——冠状动脉外科研究(CASS)尚未公布长期随访结果。大型临床研究,包括随机对照研究和非随机对照研究,按照病变冠状动脉数量和左心室功能障碍程度对患者进行亚组分析,结果均显示单支血管病变患者的生存率很高,手术并不能提高其生存率。左心室功能良好、接受内科治疗的双支血管病变和三支血管病变患者,其5年生存率目前通常超过85%,只有两项主要研究表明手术可提高其生存率。然而,大多数研究结果表明,当左心室功能障碍与双支血管病变和三支血管病变并存时,搭桥手术可延长有症状患者的生存期。不断改进的手术技术可能会扩大目前明显的微小生存差异,但在此之前,由于生存差异非常小,建议缓解心绞痛症状仍是为个体患者实施冠状动脉搭桥手术的主要指征。